Toronto-based Biossil has raised US$153 million in an all-equity financing led by the OpenAI Startup Fund, valuing the biotech at US$1 billion and giving Canada another unicorn. Biossil acquires or licenses drug candidates that previously failed to reach market, then uses AI to identify which molecules may deserve a second chance in clinical development.
The round also included Founders Fund, Quiet Capital, Modern Capital, Golden Ventures, Panache Ventures, Duke University’s endowment, and Abu Dhabi Investment Council. Biossil says the new capital will expand clinical development capacity and help it acquire additional drug candidates for its growing pipeline globally over time.
Want to know more? Check out the source code here.